Vandria
Founded 2021 · 16 employees on LinkedIn · 2 known investors
Vandria develops first-in-class orally available small molecules targeting a novel metabolic pathway to improve mitochondrial function and reduce chronic inflammation for age-related and chronic diseases of the CNS, muscle, lung, and liver. Its lead clinical asset, VNA-318, is a small molecule for CNS indications that has completed Phase I studies.
Investors · 2
Frequently asked questions
- What does Vandria do?
- Vandria develops first-in-class orally available small molecules targeting a novel metabolic pathway to improve mitochondrial function and reduce chronic inflammation for age-related and chronic diseases of the CNS, muscle, lung, and liver. Its lead clinical asset, VNA-318, is a small molecule for CNS indications that has completed Phase I studies.
- Who are Vandria's investors?
- Vandria's investors include +ND Capital, Dolby Family Ventures.